CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial
Year: 2022
Type: article
Study design: Clinical Trial
Authors: Timothy P. Hughes, Jorge E. Cortes, Delphine Réa, Michael J. Mauro, Andreas Hochhaus, Dong-Wook Kim, Koji Sasaki, Fabian Lang, Michael C. Heinrich, Massimo Breccia, Michael Deininger, Yeow-Tee Goh, Jeroen J. W.M Janssen, Moshe Talpaz, Philipp le Coutre, Shruti Kapoor, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Francois-Xavier Mahon
Institutions: South Australian Health and Medical Research Institute, The University of Adelaide, Hôpital Saint-Louis, Memorial Sloan Kettering Cancer Center, Jena University Hospital, Eulji University Uijeongbu Eulji Medical Center, The University of Texas MD Anderson Cancer Center, University Hospital Frankfurt, Oregon Health & Science University, Portland VA Medical Center, OHSU Knight Cancer Institute, Policlinico Umberto I, Sapienza University of Rome, Versiti Blood Research Institute Foundation, Singapore General Hospital, U-M Rogel Cancer Center, Charité - Universitätsmedizin Berlin, Novartis (Switzerland), Institut Bergonié
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4296468348